Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. [electronic resource]
- Endocrinology May 2009
- 2368-75 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
1945-7170
10.1210/en.2008-1540 doi
Animals Anticarcinogenic Agents--adverse effects Apolipoprotein E3--genetics Bexarotene Cholesterol Ester Transfer Proteins--genetics Drug Evaluation, Preclinical Dyslipidemias--chemically induced Humans Lipoproteins, HDL--metabolism Lipoproteins, VLDL--metabolism Male Mice Mice, Transgenic Tetrahydronaphthalenes--adverse effects Triglycerides--blood